We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
-10.3%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$3.69B
AUM Growth
-$784M
Cap. Flow
-$69.3M
Cap. Flow %
-1.88%
Top 10 Hldgs %
43.31%
Holding
160
New
14
Increased
20
Reduced
11
Closed
10

Top Buys

Rank Stock Value
1
EQRX
EQRx, Inc. Common Stock
EQRX
+$37.8M
2
KYMR icon
Kymera Therapeutics
KYMR
+$34.9M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$31.1M
4
EVO icon
Evotec
EVO
+$26.8M
5
BLU
BELLUS Health Inc.
BLU
+$21.6M

Top Sells

Rank Stock Value
1
XLRN
Acceleron Pharma
XLRN
+$172M
2
ARGX icon
argenx
ARGX
+$23.5M
3
ITOS
iTeos Therapeutics
ITOS
+$15M
4
BABA icon
Alibaba
BABA
+$14.8M
5
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$14.1M

Sector Composition

Rank Sector Weight
1 Healthcare 83.56%
2 Consumer Discretionary 6.51%
3 Financials 0.7%
4 Materials 0.48%
5 Consumer Staples 0.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APTX
51
DELISTED
Aptinyx Inc. Common Stock
APTX
$16.3M 0.44%
6,116,493
– –
INTC icon
52
CALL
Intel
INTC
$413B
$15.4M 0.42%
300,000
– –
TGTX icon
53
TG Therapeutics
TGTX
$8.19B
$15.2M 0.41%
800,000
– –
RPTX
54
DELISTED
Repare Therapeutics
RPTX
$14.8M 0.4%
700,000
+150,000
+27% +$3.53M
VERV
55
DELISTED
Verve Therapeutics
VERV
$14.7M 0.4%
400,000
– –
KURA icon
56
Kura Oncology
KURA
$793M
$14.7M 0.4%
1,050,000
– –
SQZ
57
DELISTED
SQZ Biotechnologies Company
SQZ
$14.3M 0.39%
1,606,309
– –
FMTX
58
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$14.2M 0.39%
1,000,000
– –
ALBO
59
DELISTED
Albireo Pharma Inc
ALBO
$14M 0.38%
600,000
– –
RNAC icon
60
Cartesian Therapeutics
RNAC
$218M
$13M 0.35%
133,333
– –
CYPH
61
Cypherpunk Technologies Inc
CYPH
$64M
$13M 0.35%
400,000
– –
TSHA icon
62
Taysha Gene Therapies
TSHA
$1.61B
$12.1M 0.33%
1,040,882
– –
OTLY
63
Oatly Group
OTLY
$476M
$11.9M 0.32%
75,000
– –
TPTX
64
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$11.9M 0.32%
250,000
-100,000
-29% -$4.47M
MRNS
65
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$11.9M 0.32%
1,000,000
– –
ACHL
66
DELISTED
Achilles Therapeutics
ACHL
$11.3M 0.31%
2,255,375
– –
EXAI
67
DELISTED
Exscientia Plc American Depositary Shares
EXAI
$10.9M 0.29%
+550,000
New +$11.6M
ALXO icon
68
ALX Oncology
ALXO
$262M
$10.7M 0.29%
500,000
– –
SAGE
69
CALL
DELISTED
Sage Therapeutics
SAGE
$10.6M 0.29%
+250,000
New +$10.5M
SYRS
70
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$9.78M 0.27%
300,000
+100,000
+50% +$4.05M
GRTS
71
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$9.64M 0.26%
+750,000
New +$8.31M
BDTX icon
72
Black Diamond Therapeutics
BDTX
$95.1M
$8.78M 0.24%
1,646,517
– –
LENZ
73
LENZ Therapeutics
LENZ
$179M
$8.7M 0.24%
100,000
– –
DSGN icon
74
Design Therapeutics
DSGN
$751M
$8.56M 0.23%
400,000
– –
ALPN
75
DELISTED
Alpine Immune Sciences Inc
ALPN
$8.21M 0.22%
593,030
– –
1 2
3
4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q4 2021 Portfolio in Review

As of Q4 2021, Artal Group held 160 positions worth $3.69B, down 18% from $4.47B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Artal Group's Q4 2021 filing shows 14 new, 20 increased, 11 reduced and 10 closed positions. Its largest new stake was EQRx, Inc. Common Stock: 4,000,000 shares worth $27.3M. The largest sale was Acceleron Pharma, an estimated $172M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 82% a quarter earlier, followed by Consumer Discretionary and Financials.

  • Artal Group's largest Q4 2021 buy was EQRx, Inc. Common Stock: 4,000,000 shares worth $27.3M.
  • Artal Group added most to Kymera Therapeutics in Q4 2021, an estimated $34.9M increase.
  • Artal Group's biggest Q4 2021 reduction was argenx, cutting an estimated $23.5M.
  • Artal Group fully exited Acceleron Pharma in Q4 2021, selling an estimated $172M.
  • Artal Group's ten largest holdings make up 43% of its $3.69B portfolio in Q4 2021.
  • Artal Group opened 14 new positions and closed 10 in Q4 2021.
  • Artal Group's portfolio value fell 18% quarter-over-quarter to $3.69B.

Based on Artal Group's 13F filing for Q4 2021, filed 11 Feb 2022.